Pivanex for Relapsed Chronic Lymphocytic Leukemia Treatment

Chronic lymphocytic leukemia (CLL) is a condition where mature lymphocytes, a type of white blood cell, accumulate and do not die as they should. This results in limited therapy options, especially when standard chemotherapy treatments fail. A new class of drugs, known as histone deacetylase inhibitors (HDACs), is being explored for treating various cancers. One such HDAC inhibitor is Pivanex, which has shown promise in inducing the death of CLL lymphocytes in lab settings. This study aims to understand the effects of Pivanex in patients with CLL, potentially offering a new treatment option for this condition. This is an open-label trial, meaning everyone involved knows the treatment being used. Participants, who have relapsed CLL, will receive 2.5 g/m2 of Pivanex intravenously over 6 hours daily for three days. This treatment cycle will repeat every 21 days until the disease progresses or the patient is withdrawn for specific reasons outlined in the study protocol. The study will measure the response rate to Pivanex, time to disease progression, and the safety profile of the drug in CLL patients. Disease status will be assessed before every odd-numbered treatment cycle using established CLL guidelines.